Development of Dose-Volume Relation Model for Gamma Knife Surgery of Non-Skull Base Intracranial Meningiomas
- Department of Neurosurgery, Seoul National University College of Medicine, Seoul (Korea, Republic of)
Purpose: To provide a dose-volume relationship for gamma knife surgery (GKS) of non-skull base intracranial meningiomas. Methods and Materials: The radiologic outcomes of GKS of 82 imaging-defined benign meningiomas located at non-skull base areas were analyzed. A total of 80 patients were included and all underwent treatment with GKS as the first and the only treatment modality. The mean patient age was 55.0 years (range, 26-78) and the mean tumor volume was 5.6 cm{sup 3} (range, 0.5-16.8). On average, 14.6 Gy (range, 10-20) was applied to the 50% isodose surface. The binary logistic regression method was applied to find prognostic factors of signal change (SC) on T{sub 2}-weighted magnetic resonance imaging after GKS. Results: The actuarial tumor control rate was 91.6% at 5 years. A total of 29 lesions (35.4%) showed newly developed or aggravated SCs. The volume irradiated {>=}14 Gy was the only statistically significant (p < .01) prognostic factor of SC. A dose-volume relation model obtained from the cases without SC estimated a 12.2% SC probability. Conclusion: This model can be used in GKS to treat small- to medium-size (<9.2 cm{sup 3}) non-skull base meningiomas.
- OSTI ID:
- 21276892
- Journal Information:
- International Journal of Radiation Oncology, Biology and Physics, Vol. 74, Issue 4; Other Information: DOI: 10.1016/j.ijrobp.2008.09.007; PII: S0360-3016(08)03430-5; Copyright (c) 2009 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA); ISSN 0360-3016
- Country of Publication:
- United States
- Language:
- English
Similar Records
The Importance of the Conformality, Heterogeneity, and Gradient Indices in Evaluating Gamma Knife Radiosurgery Treatment Plans for Intracranial Meningiomas
Spot Scanning-Based Proton Therapy for Intracranial Meningioma: Long-Term Results From the Paul Scherrer Institute